Idiopathic Pulmonary Fibrosis Market Growth To $6.16 Billion By 2030: What’s Driving The Expansion?

Idiopathic Pulmonary Fibrosis Market Report

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Idiopathic Pulmonary Fibrosis Market Set To Climb From $4.66 Billion In 2026 To $6.16 Billion By 2030

The idiopathic pulmonary fibrosis market size has shown strong growth in recent years. It is forecast to grow from $4.37 billion in 2025 to $4.66 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.7%. The expansion observed in the historic period can be attributed to several factors, including limited treatment options for fibrotic lung diseases, a rising prevalence of the aging population, improved clinical recognition of IPF, the approval of nintedanib and pirfenidone, and increased hospital-based management of chronic lung disorders.

The idiopathic pulmonary fibrosis market is anticipated to show considerable expansion over the forthcoming years. It is projected to achieve a size of $6.16 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2%. This growth during the forecast period is fueled by increasing research investments in pulmonary fibrosis, the development of advanced antifibrotic drugs, greater reliance on real-world evidence in making treatment decisions, the broadening of online and specialty pharmacy channels, and a heightened awareness of rare respiratory illnesses. Key trends expected in the forecast period include the rising adoption of antifibrotic therapies, a stronger emphasis on early and accurate diagnosis, the growing implementation of combination drug therapies, an expansion of home-based and long-term disease management solutions, and increased involvement in clinical trials for new therapeutic options.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=25538632&type=smp&name=Idiopathic%20Pulmonary%20Fibrosis%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Idiopathic Pulmonary Fibrosis Market Growth Factors Behind Sustained Expansion

The idiopathic pulmonary fibrosis market is anticipated to expand due to an expanding geriatric demographic. This demographic consists of the elderly or senior individuals in a society. With advancing age, individuals experience lung changes, increasing their vulnerability to respiratory conditions like IPF. This heightened susceptibility linked to age fuels the demand for IPF therapies. For example, reports from the Population Reference Bureau, a US-based non-profit organization, indicated in January 2024 that the U.S. population aged 65 and above is projected to grow from 58 million in 2022 to 82 million by 2050, representing a 47% surge. Consequently, the percentage of this age bracket within the total U.S. population is set to increase from 17% to 23% over this timeframe. Hence, the expanding geriatric population is a significant factor propelling the growth of the idiopathic pulmonary fibrosis market.

Idiopathic Pulmonary Fibrosis Market Segment Trends And Revenue Contributors

The idiopathic pulmonary fibrosis market covered in this report is segmented –

1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types

2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes Of Action

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers

5) By End Users: Hospitals And Clinics, Other End Users

Subsegments:

1) By Nintedanib: Indications, Dosage Forms, Administration Routes

2) By Pirfenidone: Indications, Dosage Forms, Administration Routes

3) By Other Drug Types: Specific Agents Or Classes, Emerging Therapies, Combination Therapies

Idiopathic Pulmonary Fibrosis Market Industry Trends Fueling Future Revenue Growth

Leading companies in the idiopathic pulmonary fibrosis (IPF) market are prioritizing new products, specifically anti-fibrotic small-molecule inhibitors, to maintain their competitive edge. These inhibitors are pharmaceutical compounds engineered to target and stop fibrotic processes within the body. An example of this is Insilico Medicine, a US-based clinical-stage biotechnology firm leveraging generative artificial intelligence (AI), which declared the start of Phase II clinical trials for INS018_055 in June 2023. This compound is notable as the globe’s inaugural anti-fibrotic small molecule inhibitor created using generative AI. This significant event involved administering the initial dose to trial participants in a randomized, double-blind, placebo-controlled study. The trial’s objective is to assess the safety, tolerability, pharmacokinetics, and initial effectiveness of a 12-week oral dosage of INS018_055 in individuals suffering from idiopathic pulmonary fibrosis (IPF). This cutting-edge method utilizes AI in drug development, indicating a promising step forward in treating idiopathic pulmonary fibrosis (IPF) conditions.

Idiopathic Pulmonary Fibrosis Market Competitive Landscape: Which Companies Lead The Industry?

Major companies operating in the idiopathic pulmonary fibrosis market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.

View The Full Idiopathic Pulmonary Fibrosis Market Report:

https://thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Idiopathic Pulmonary Fibrosis Market Top Region By Revenue And Market Share

North America was the largest region in the idiopathic pulmonary fibrosis market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model